肿瘤细胞治疗研究
英文原题：CD70-targeted cancer theranostics: Progress and challenges.
CD70 是一种肿瘤相关抗原，在透明细胞肾细胞癌（ccRCC）、鼻咽癌和淋巴瘤等中表达升高，而在健康组织中极少存在。
CD70是一种肿瘤相关抗原，在透明细胞肾细胞癌（ccRCC）、鼻咽癌和淋巴瘤等多种肿瘤中表达升高，而在健康组织中表达极少。CD70已成为分子影像、靶向治疗和免疫治疗的有前景标志物。采用单域抗体来源示踪剂（如[18F]RCCB6和[68Ga]Ga-NOTA-RCCB6）的免疫PET成像具有出色的诊断精确度，可检测ccRCC常见及罕见转移灶，提高分期准确性并支持早期干预。除诊断外，CD70靶向成像还可依据CD70表达水平对患者分层，从而优化CAR-T细胞和抗体偶联药物等新兴疗法的患者选择。该技术还支持实时监测治疗应答，以便动态调整治疗。将这些成像工具纳入临床流程，可提高CD70表达型肿瘤个体化治疗的效果。放射诊疗一体化策略还可同时实现肿瘤诊断与治疗，为CD70阳性肿瘤的精准管理开辟新前景。
CD70, a tumor-associated antigen, exhibits elevated expression in clear cell renal cell carcinoma (ccRCC), nasopharyngeal carcinoma, and lymphoma, among others, with minimal presence in healthy tissues. CD70 has emerged as a promising biomarker for molecular imaging, targeted therapies, and immunotherapies. ImmunoPET imaging with single-domain antibody-derived tracers, such as [ 18 F]RCCB6 and [ 68 Ga]Ga-NOTA-RCCB6, demonstrates exceptional diagnostic precision, identifying both common and rare metastases from ccRCC. This capability enhances staging accuracy and further enables early intervention. Beyond diagnostics, CD70-targeted imaging optimizes patient selection for emerging therapies, such as CAR-T cells and antibody-drug conjugates, by stratifying candidates based on their CD70 expression levels. It also supports real-time monitoring of therapeutic responses, enabling dynamic adjustments to treatment. The integration of these imaging tools into clinical workflows enhances personalized treatment efficacy for CD70-expressing cancers. Radiotheranostic strategies can further allow the simultaneous diagnosis and treatment of malignancies, opening new horizons for the precise management of CD70 + tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
